Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies.
BACKGROUND: Natural killer cells are an important component of the innate immune system. Anti-cancer therapies utilizing monoclonal antibodies also rely on the cytotoxicity of NK cells for their effectiveness. Here, we study the dynamics of NK cell cytotoxicity. METHODOLOGY/PRINCIPAL FINDINGS: We ob...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2007-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC1828617?pdf=render |
id |
doaj-6c7bd19792714d7199b9f68a499c50e7 |
---|---|
record_format |
Article |
spelling |
doaj-6c7bd19792714d7199b9f68a499c50e72020-11-25T01:35:51ZengPublic Library of Science (PLoS)PLoS ONE1932-62032007-01-0123e32610.1371/journal.pone.0000326Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies.Rauf BhatCarsten WatzlBACKGROUND: Natural killer cells are an important component of the innate immune system. Anti-cancer therapies utilizing monoclonal antibodies also rely on the cytotoxicity of NK cells for their effectiveness. Here, we study the dynamics of NK cell cytotoxicity. METHODOLOGY/PRINCIPAL FINDINGS: We observe that IL-2 activated human NK cells can serially hit multiple targets. Using functional assays, we demonstrate that on an average, a single IL-2 activated NK cell can kill four target cells. Data using live video microscopy suggest that an individual NK cell can make serial contacts with multiple targets and majority of contacts lead to lysis of target cells. Serial killing is associated with a loss of Perforin and Granzyme B content. A large majority of NK cells survive serial killing, and IL-2 can replenish their granular stock and restore the diminished cytotoxicity of 'exhausted' NK cells. IL-2 and IL-15 are equally effective in enhancing the killing frequency of resting NK cells. Significantly, Rituximab, a therapeutic monoclonal antibody increases the killing frequency of both resting and IL-2 activated NK cells. CONCLUSION/SIGNIFICANCE: Our data suggest that NK cell-based therapies for overcoming tumors rely on their serial killing ability. Therefore, strategies augmenting the killing ability of NK cells can boost the immune system and enhance the effectiveness of monoclonal antibody-based therapies.http://europepmc.org/articles/PMC1828617?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Rauf Bhat Carsten Watzl |
spellingShingle |
Rauf Bhat Carsten Watzl Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies. PLoS ONE |
author_facet |
Rauf Bhat Carsten Watzl |
author_sort |
Rauf Bhat |
title |
Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies. |
title_short |
Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies. |
title_full |
Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies. |
title_fullStr |
Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies. |
title_full_unstemmed |
Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies. |
title_sort |
serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2007-01-01 |
description |
BACKGROUND: Natural killer cells are an important component of the innate immune system. Anti-cancer therapies utilizing monoclonal antibodies also rely on the cytotoxicity of NK cells for their effectiveness. Here, we study the dynamics of NK cell cytotoxicity. METHODOLOGY/PRINCIPAL FINDINGS: We observe that IL-2 activated human NK cells can serially hit multiple targets. Using functional assays, we demonstrate that on an average, a single IL-2 activated NK cell can kill four target cells. Data using live video microscopy suggest that an individual NK cell can make serial contacts with multiple targets and majority of contacts lead to lysis of target cells. Serial killing is associated with a loss of Perforin and Granzyme B content. A large majority of NK cells survive serial killing, and IL-2 can replenish their granular stock and restore the diminished cytotoxicity of 'exhausted' NK cells. IL-2 and IL-15 are equally effective in enhancing the killing frequency of resting NK cells. Significantly, Rituximab, a therapeutic monoclonal antibody increases the killing frequency of both resting and IL-2 activated NK cells. CONCLUSION/SIGNIFICANCE: Our data suggest that NK cell-based therapies for overcoming tumors rely on their serial killing ability. Therefore, strategies augmenting the killing ability of NK cells can boost the immune system and enhance the effectiveness of monoclonal antibody-based therapies. |
url |
http://europepmc.org/articles/PMC1828617?pdf=render |
work_keys_str_mv |
AT raufbhat serialkillingoftumorcellsbyhumannaturalkillercellsenhancementbytherapeuticantibodies AT carstenwatzl serialkillingoftumorcellsbyhumannaturalkillercellsenhancementbytherapeuticantibodies |
_version_ |
1725065815362895872 |